A Perspective on Therapeutic Targeting Against Ubiquitin Ligases to Stabilize Tumor Suppressor Proteins

Simple Summary During cancer development, tumor suppressor proteins undergo inactivation due to genetic, epigenetic, or post-translational alterations. While the concept of reactivating tumor suppressor proteins has been appreciated as a potential anti-cancer therapeutic strategy for decades, progress in developing therapies that target tumor suppressor proteins has lagged behind the successful development of therapies targeting oncoproteins such as protein kinases. Here, we review the status and potential of therapeutic targeting against ubiquitin ligases as a promising approach to stabilize and reactivate tumor suppressor proteins.

• Publication year

  2025

• Venue

  Cancers

• Publication date

  2025-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3390/cancers17040626PMID 40002221PMCID 11853300
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• LOC644656 promotes cisplatin resistance in cervical cancer by recruiting ZNF143 and activating the transcription of E6-AP.

  2024cited by this paper
• TP53 mutations in cancer: Molecular features and therapeutic opportunities (Review)

  2024cited by this paper
• MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future

  2024influential reference
• p53 Immunohistochemistry staining patterns and prognosis significance in 212 cases of non-endometrioid endometrial cancer.

  2024cited by this paper
• Induced protein degradation for therapeutics: past, present, and future

  2024cited by this paper
• Cancer epigenetics: from laboratory studies and clinical trials to precision medicine

  2024cited by this paper
• Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules

  2024cited by this paper
• KLHL20 and its role in cell homeostasis: A new perspective and therapeutic potential.

  2024cited by this paper
• E3 ubiquitin ligase WWP2 as a promising therapeutic target for diverse human diseases.

  2024cited by this paper
• KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors

  2024cited by this paper
• Roles of post-translational modifications of UHRF1 in cancer

  2024cited by this paper
• Properties of FDA-approved small molecule protein kinase inhibitors: a 2024 update.

  2024cited by this paper
• Skp2: A critical molecule for ubiquitination and its role in cancer.

  2024cited by this paper
• Structure of the p53 degradation complex from HPV16

  2024cited by this paper
• Structural insights into the functional mechanism of the ubiquitin ligase E6AP

  2024cited by this paper
• Brightline-1: phase II/III trial of the MDM2-p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS.

  2023cited by this paper
• Transcriptional reprogramming restores UBE3A brain-wide and rescues behavioral phenotypes in an Angelman Syndrome mouse model.

  2023cited by this paper
• Targeted inhibition of SCFSKP2 confers anti-tumor activities resulting in a survival benefit in osteosarcoma

  2023cited by this paper
• Tissue specificity and spatio-temporal dynamics of the p53 transcriptional program

  2023cited by this paper
• Discovery of reactive peptide inhibitors of human papillomavirus oncoprotein E6

  2023cited by this paper
• Skp2-mediated MLKL degradation confers cisplatin-resistant in non-small cell lung cancer cells

  2023cited by this paper
• Targeting of HPV E6 at the binding sites to the host-cell E6AP, p53, and the endoplasmic reticulum-resident chaperone, GRP78

  2023cited by this paper
• Small-molecule compounds inhibiting S-phase kinase-associated protein 2: A review

  2023cited by this paper
• The roles of E3 ubiquitin ligases in cancer progression and targeted therapy

  2023cited by this paper
• Pan-cancer genomic analysis shows hemizygous PTEN loss tumors are associated with immune evasion and poor outcome

  2023cited by this paper
• Advancements in MDM2 inhibition: Clinical and pre-clinical investigations of combination therapeutic regimens

  2023cited by this paper
• PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer

  2023cited by this paper
• SKP2 knockout in Rb1/p53 deficient mouse models of osteosarcoma induces immune infiltration and drives a transcriptional program with a favorable prognosis.

  2023cited by this paper
• MDM2 inhibition enhances immune checkpoint inhibitor efficacy by increasing IL-15 and MHC class II production.

  2023cited by this paper
• Clinical significance of FBXW7 loss of function in human cancers

  2022cited by this paper
• Modulating the expression of tumor suppressor genes using activating oligonucleotide technologies as a therapeutic approach in cancer

  2022cited by this paper
• Taxifolin and Lucidin as Potential E6 Protein Inhibitors: p53 Function Re-Establishment and Apoptosis Induction in Cervical Cancer Cells

  2022cited by this paper
• Small-molecule MDM2 inhibitors in clinical trials for cancer therapy.

  2022cited by this paper
• MDM2 E3 ligase activity is essential for p53 regulation and cell cycle integrity

  2022cited by this paper
• Targeting the untargetable: RB1-deficient tumours are vulnerable to Skp2 ubiquitin ligase inhibition

  2022cited by this paper
• Correction: MDM2 E3 ligase activity is essential for p53 regulation and cell cycle integrity

  2022cited by this paper
• Unraveling the Potential Role of NEDD4-like E3 Ligases in Cancer

  2022cited by this paper
• Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders

  2022cited by this paper
• Mutational landscape of cancer-driver genes across human cancers

  2022cited by this paper
• Regulation of p27 (Kip1) by Ubiquitin E3 Ligase RNF6

  2022cited by this paper
• Induction of zinc finger protein RNF6 auto-ubiquitination for the treatment of myeloma and chronic myeloid leukemia

  2022cited by this paper
• Ubiquitination/de-ubiquitination: A promising therapeutic target for PTEN reactivation in cancer.

  2022cited by this paper
• The p53 network: cellular and systemic DNA damage responses in cancer and aging.

  2022cited by this paper
• Molecular docking of DS-3032B, a mouse double minute 2 enzyme antagonist with potential for oncology treatment development

  2022cited by this paper
• Targeting RFWD2 as an Effective Strategy to Inhibit Cellular Proliferation and Overcome Drug Resistance to Proteasome Inhibitor in Multiple Myeloma

  2021cited by this paper
• The E3 Ubiquitin Ligase NEDD4-1 Mediates Temozolomide-Resistant Glioblastoma through PTEN Attenuation and Redox Imbalance in Nrf2–HO-1 Axis

  2021cited by this paper
• Identification of a Catalytic Active but Non-Aggregating MDM2 RING Domain Variant

  2021cited by this paper
• E3 ubiquitin ligase RNF126 affects bladder cancer progression through regulation of PTEN stability

  2021cited by this paper
• Elevated FBXO45 promotes liver tumorigenesis through enhancing IGF2BP1 ubiquitination and subsequent PLK1 upregulation

  2021cited by this paper
• Editorial: Novel Combination Therapies for the Treatment of Solid Cancers

  2021cited by this paper
• p53 signaling in cancer progression and therapy

  2021cited by this paper
• Emerging Roles of SKP2 in Cancer Drug Resistance

  2021cited by this paper
• PPI Modulators of E6 as Potential Targeted Therapeutics for Cervical Cancer: Progress and Challenges in Targeting E6

  2021cited by this paper
• TRIM25 activates AKT/mTOR by inhibiting PTEN via K63-linked polyubiquitination in non-small cell lung cancer

  2021cited by this paper
• Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting.

  2021cited by this paper
• Smurf1 silencing restores PTEN expression that ameliorates progression of human glioblastoma and sensitizes tumor cells to mTORC1/C2 inhibitor Torin1

  2021cited by this paper
• The roles and regulation of MDM2 and MDMX: it is not just about p53

  2021cited by this paper
• Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors

  2021cited by this paper
• The degradation of Rap1GAP via E6AP-mediated ubiquitin-proteasome pathway is associated with HPV16/18-infection in cervical cancer cells

  2021cited by this paper
• Ubiquitin ligases in cancer: functions and clinical potentials.

  2021cited by this paper
• High Expression of WWP1 Associates with Tumor Progression in Papillary Thyroid Cancer

  2021cited by this paper
• Targeted Inhibition of the E3 Ligase SCFSkp2/Cks1 Has Antitumor Activity in RB1-Deficient Human and Mouse Small-Cell Lung Cancer

  2020cited by this paper
• RNF6 as an Oncogene and Potential Therapeutic Target—A Review

  2020cited by this paper
• Role of Ubiquitination in PTEN Cellular Homeostasis and Its Implications in GB Drug Resistance

  2020cited by this paper
• The p53/MDM2/MDMX-targeted therapies—a clinical synopsis

  2020cited by this paper
• XIAP’s Profile in Human Cancer

  2020cited by this paper
• FBXO22 degrades nuclear PTEN to promote tumorigenesis

  2020cited by this paper
• PTEN Alterations and Their Role in Cancer Management: Are We Making Headway on Precision Medicine?

  2020cited by this paper
• FBXO45 is a potential therapeutic target for cancer therapy

  2020cited by this paper
• Effect of murine double‐minute 2 inhibitors in preclinical models of advanced clear cell carcinomas originating from ovaries and kidneys

  2020cited by this paper
• Tripartite motif protein 25 is associated with epirubicin resistance in hepatocellular carcinoma cells via regulating PTEN/AKT pathway

  2020cited by this paper
• WWP1 Gain-of-Function Inactivation of PTEN in Cancer Predisposition.

  2020cited by this paper
• Regulating tumor suppressor genes: post-translational modifications

  2020cited by this paper
• The HECT E3 Ligase E6AP/UBE3A as a Therapeutic Target in Cancer and Neurological Disorders

  2020cited by this paper
• A novel small-molecule inhibitor of the human papillomavirus E6-p53 interaction that reactivates p53 function and blocks cancer cells growth.

  2019cited by this paper
• TRIM27 promotes the development of esophagus cancer via regulating PTEN/AKT signaling pathway

  2019cited by this paper
• p27/Kip1 functions as a tumor suppressor and oncoprotein in osteosarcoma

  2019cited by this paper
• ATM Regulated PTEN Degradation Is XIAP E3 Ubiquitin Ligase Mediated in p85α Deficient Cancer Cells and Influence Platinum Sensitivity

  2019cited by this paper
• Therapeutic targeting of the E3 ubiquitin ligase SKP2 in T-ALL

  2019cited by this paper
• PTEN in Hereditary and Sporadic Cancer.

  2019cited by this paper
• Anti-tumor activity of dual inhibition of phosphatidylinositol 3-kinase and MDM2 against clear cell ovarian carcinoma.

  2019cited by this paper
• Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway

  2019cited by this paper
• MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment

  2019cited by this paper
• E6AP goes viral: the role of E6AP in viral- and non-viral-related cancers.

  2019cited by this paper
• Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials

  2019cited by this paper
• Characterization of Tumor-Suppressor Gene Inactivation Events in 33 Cancer Types

  2019cited by this paper
• CPSF7 regulates liver cancer growth and metastasis by facilitating WWP2-FL and targeting the WWP2/PTEN/AKT signaling pathway.

  2019cited by this paper
• FBXO45-MYCBP2 regulates mitotic cell fate by targeting FBXW7 for degradation

  2018cited by this paper
• PML: Regulation and multifaceted function beyond tumor suppression

  2018cited by this paper
• Loss of Tumor Suppressor Gene Function in Human Cancer: An Overview

  2018cited by this paper
• WWP2 is a physiological ubiquitin ligase for phosphatase and tensin homolog (PTEN) in mice

  2018cited by this paper
• Small Molecule Modulators of RING-Type E3 Ligases: MDM and Cullin Families as Targets

  2018cited by this paper
• HUWE1 controls the development of non-small cell lung cancer through down-regulation of p53

  2018cited by this paper
• Identifying the ubiquitination targets of E6AP by orthogonal ubiquitin transfer

  2017cited by this paper
• Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapy: Progress and Challenges.

  2017cited by this paper
• Therapeutic vaccines for high-risk HPV-associated diseases

  2017cited by this paper
• PTEN is a protein phosphatase that targets active PTK6 and inhibits PTK6 oncogenic signaling in prostate cancer

  2017cited by this paper
• Essential Roles of E3 Ubiquitin Ligases in p53 Regulation

  2017cited by this paper
• Expression of WW domain-containing protein 2 is correlated with pathological grade and recurrence of glioma.

  2017cited by this paper
• E6AP promotes prostate cancer by reducing p27 expression

  2017cited by this paper

• The ubiquitination–autophagy axis in cancer therapy resistance: mechanistic insights and therapeutic opportunities

  2026cites this paper
• Alcohol, Anti-HIV Drugs, and/or Hippuric Acid Deteriorate Cellular Stresses in Senescent Hepatocytes and Aging Murine Liver

  2025cites this paper